• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人血浆和血小板中凝血因子V的放射免疫测定

Radioimmunoassay of factor V in human plasma and platelets.

作者信息

Tracy P B, Eide L L, Bowie E J, Mann K G

出版信息

Blood. 1982 Jul;60(1):59-63.

PMID:7082847
Abstract

Homogeneous, single-chain human factor V was used to develop a double antibody competition radioimmunoassay to measure factor V concentrations in plasma and platelets. Standard curves were constructed that allow for the detection of as little as 20 ng factor V/ml of plasma. Normal factor V concentrations range from 4 to 14 micrograms/ml of plasma with an average value of 7.0 +/- 2.0 micrograms/ml (n = 64). No correlation was observed between antigen levels and age or sex. The radioimmunoassay data are consistent with factor V clotting assays, providing freshly drawn plasma is used in the bioassay. Radioimmunoassay of washed platelets indicate that 0.63-1.93 microgram of factor V is present per 2.5 X 10(8) platelets (4612-14128 molecules of the factor V platelet). When normalized to individual hematocrits and platelet count, the data indicated that platelets contribute approximately 18%-25% of the factor V found in whole blood. In addition, two individuals with functionally deficient factor V were examined and found to be deficient in both antigen and activity.

摘要

使用同源单链人凝血因子V开发了一种双抗体竞争放射免疫测定法,用于测量血浆和血小板中的凝血因子V浓度。构建的标准曲线能够检测低至20 ng凝血因子V/毫升血浆。正常凝血因子V浓度范围为4至14微克/毫升血浆,平均值为7.0±2.0微克/毫升(n = 64)。未观察到抗原水平与年龄或性别之间存在相关性。如果生物测定中使用的是新鲜采集的血浆,放射免疫测定数据与凝血因子V凝血测定结果一致。对洗涤后的血小板进行放射免疫测定表明,每2.5×10⁸个血小板中存在0.63 - 1.93微克凝血因子V(凝血因子V血小板的4612 - 14128个分子)。当根据个体血细胞比容和血小板计数进行标准化时,数据表明血小板贡献了全血中约18% - 25%的凝血因子V。此外,对两名凝血因子V功能缺陷的个体进行了检查,发现他们的抗原和活性均有缺陷。

相似文献

1
Radioimmunoassay of factor V in human plasma and platelets.人血浆和血小板中凝血因子V的放射免疫测定
Blood. 1982 Jul;60(1):59-63.
2
The localization of factor V within normal human platelets and the demonstration of a platelet-factor V antigen in congenital factor V deficiency.正常人血小板中因子V的定位以及先天性因子V缺乏症中血小板因子V抗原的证实。
Br J Haematol. 1975 Mar;29(3):405-12. doi: 10.1111/j.1365-2141.1975.tb01838.x.
3
Factor V (Quebec): a bleeding diathesis associated with a qualitative platelet Factor V deficiency.因子V(魁北克型):一种与血小板因子V质量缺陷相关的出血素质。
J Clin Invest. 1984 Oct;74(4):1221-8. doi: 10.1172/JCI111531.
4
Patients with congenital factor V deficiency have decreased factor Xa binding sites on their platelets.先天性因子V缺乏症患者血小板上的因子Xa结合位点减少。
J Clin Invest. 1978 Oct;62(4):824-31. doi: 10.1172/JCI109194.
5
Evidence that endotoxins enhance the factor X activator activity of washed human platelets.内毒素增强人洗涤血小板因子X激活剂活性的证据。
Br J Haematol. 1978 Feb;38(2):243-9. doi: 10.1111/j.1365-2141.1978.tb01040.x.
6
Radioimmunoassay of human platelet thrombospondin: different patterns of thrombospondin and beta-thromboglobulin antigen secretion and clearance from the circulation.人血小板凝血酶敏感蛋白的放射免疫测定:凝血酶敏感蛋白和β-血小板球蛋白抗原分泌及从循环中清除的不同模式
J Lab Clin Med. 1985 Dec;106(6):690-700.
7
Residual platelet factor V ensures thrombin generation in patients with severe congenital factor V deficiency and mild bleeding symptoms.严重先天性因子 V 缺乏症伴轻度出血症状患者中残留的血小板因子 V 可确保凝血酶生成。
Blood. 2010 Jan 28;115(4):879-86. doi: 10.1182/blood-2009-08-237719. Epub 2009 Oct 27.
8
Heterogeneity of human factor V deficiency. Evidence for the existence of antigen-positive variants.人凝血因子V缺乏的异质性。抗原阳性变体存在的证据。
J Clin Invest. 1983 Aug;72(2):493-503. doi: 10.1172/jci110997.
9
Biosynthesis of factor V in isolated guinea pig megakaryocytes.豚鼠分离巨核细胞中凝血因子V的生物合成
J Clin Invest. 1985 Feb;75(2):339-46. doi: 10.1172/JCI111706.
10
Association of factor V activity with membranous vesicles released from human platelets: requirement for platelet stimulation.
Thromb Res. 1985 Jul 1;39(1):49-61. doi: 10.1016/0049-3848(85)90121-5.

引用本文的文献

1
Studying the Effects of Oral Contraceptives on Coagulation Using a Mathematical Modeling Approach.使用数学建模方法研究口服避孕药对凝血的影响。
Math Model Womens Health (2024). 2024;155:83-132. doi: 10.1007/978-3-031-58516-6_4. Epub 2024 Mar 28.
2
Autoimmune Acquired Factor V Deficiency in a Patient With Pancreatic Cancer Complicated by Cholangitis: A Rare Coagulopathy With a Favorable Course.一名胰腺癌合并胆管炎患者的自身免疫性获得性因子V缺乏症:一种病程良好的罕见凝血病。
Cureus. 2025 Jul 14;17(7):e87946. doi: 10.7759/cureus.87946. eCollection 2025 Jul.
3
Basic regions of factor V and tissue factor pathway inhibitor mediate heavy chain and acidic region interactions on factor V revealed by tethered chemical cleavage.
通过连接化学切割揭示的凝血因子V和组织因子途径抑制剂的基本区域介导凝血因子V重链与酸性区域的相互作用。
J Thromb Haemost. 2025 Aug;23(8):2449-2460. doi: 10.1016/j.jtha.2025.04.028. Epub 2025 May 12.
4
Exploring Biomarkers to Predict Thrombogenic Risk in Pregnancy.探索预测妊娠血栓形成风险的生物标志物。
J Clin Med. 2025 Jan 31;14(3):932. doi: 10.3390/jcm14030932.
5
A case of unusual acquired factor V deficiency.一例罕见的获得性凝血因子V缺乏症病例。
World J Emerg Med. 2023;14(1):78-80. doi: 10.5847/wjem.j.1920-8642.2023.003.
6
"iPSC-derived liver organoids and inherited bleeding disorders: Potential and future perspectives".诱导多能干细胞衍生的肝类器官与遗传性出血性疾病:潜力与未来展望
Front Physiol. 2023 Jan 13;14:1094249. doi: 10.3389/fphys.2023.1094249. eCollection 2023.
7
Inhibition of platelet-surface-bound proteins during coagulation under flow I: TFPI.在流动条件下凝血过程中抑制血小板表面结合蛋白 I:TFPI。
Biophys J. 2023 Jan 3;122(1):99-113. doi: 10.1016/j.bpj.2022.11.023. Epub 2022 Nov 21.
8
A Novel Phenotype of the Factor 5 Gene Mutation (Homozygote Met1736Val and Heterozygote Asp68His) Is Associated With Moderate Factor V Deficiency.因子Ⅴ基因突变(纯合子Met1736Val和杂合子Asp68His)的一种新表型与中度因子Ⅴ缺乏相关。
Front Med (Lausanne). 2022 Jun 9;9:870269. doi: 10.3389/fmed.2022.870269. eCollection 2022.
9
Exploratory Investigation of the Plasma Proteome Associated with the Endotheliopathy of Trauma.创伤性内皮病相关血浆蛋白质组学的探索性研究。
Int J Mol Sci. 2022 Jun 1;23(11):6213. doi: 10.3390/ijms23116213.
10
Generation of an anticoagulant aptamer that targets factor V/Va and disrupts the FVa-membrane interaction in normal and COVID-19 patient samples.生成一种针对因子 V/Va 的抗凝适体,并在正常和 COVID-19 患者样本中破坏 FVa-膜相互作用。
Cell Chem Biol. 2022 Feb 17;29(2):215-225.e5. doi: 10.1016/j.chembiol.2022.01.009. Epub 2022 Feb 2.